As the gold standard for diagnosing Pause, Afib and other arrhythmias is to elucidate the symptom-electrocardiograph (ECG) correlation.
We believe that with the CM 100 technology we overcome all these limitations and, several cost-effectiveness analysis has indicated that the improvement in diagnostic yield offsets the cost of the ELR and that they are an economically attractive alternative when compared to Holter monitoring and the use of ELR could be viewed as a first-choice tool for patients with early recurrence of Pause, Afib and other Arrhythmias types and should be considered for patients for long-term ECG monitoring before ILR.
